Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

3 Trades On Eli Lilly Stock As Pharma Investors Await Q4 Results

By Investing.com (Tezcan Gecgil/Investing.com )Stock MarketsJan 10, 2022 08:18AM ET
www.investing.com/analysis/3-trades-on-eli-lilly-stock-as-pharma-investors-await-q4-results-200614167
3 Trades On Eli Lilly Stock As Pharma Investors Await Q4 Results
By Investing.com (Tezcan Gecgil/Investing.com )   |  Jan 10, 2022 08:18AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
  • LLY, one of the best-performing pharma stocks in 2021, was down over 6% in the first week of the new year.
  • Wall Street concurs that innovation across its core therapeutic areas has meant increased revenue and EPS numbers for Eli Lilly.
  • Long-term investors could consider buying the dips in Lilly shares, especially if they decline toward $250 or below.

Shares of pharma giant Eli Lilly and Company (NYSE:LLY) returned almost 56% in the past year. Yet, LLY stock has declined over 6% since the beginning of the year.

LLY Weekly TTM
LLY Weekly TTM

On Jan. 7, shares ended the week at $259.50. For comparison, the Dow Jones U.S. Pharmaceuticals Index is up 18.2% over the past 12 months but lost close to 2% in the first week of 2022.

On Dec. 16, LLY shares came close to $284, and hit a record high. The stock’s 52-week range has been $161.78 - $283.80, while the market capitalization (cap) stands at $248.2 billion.

Eli Lily focuses on four therapeutic areas: diabetes and obesity, immunology, oncology and neuroscience. It also has an antibody treatment against COVID-19, to which the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA).

Management released its Q3 figures on Oct. 26. Revenue of $6.78 billion increased 18% year-over-year. When excluding revenue from COVID-19 therapies, the top line increase was 11% during the same period. On a non-GAAP basis, net income increased 37% YOY to $1.764 billion, while adjusted EPS increased 38% YOY and came in at $1.94. A year ago, comparable metrics had been $1.29 billion and $1.41.

On the results, CEO David A. Ricks said:

”Lilly demonstrated strong performance again this quarter. Revenue attributable to our newer medicines grew more than 35% and represented nearly 60% of our core business, an important indicator of our long-term growth potential.”

Meanwhile, on Dec. 15, the Indianapolis, Indiana-based company said it expected 2021 revenue to be between $28.0-$28.3 billion and adjusted EPS to come in the range of $8.15-$8.20. For this year, on the other hand, Lilly expects 2022 top line to be between $27.8-$28.3 billion and EPS to be $8.50-$8.65.

Prior to the release of the quarterly results in late October, Lilly shares were trading around $248. Then, on Dec.16, it saw a record high of $283.90. But shares finished the first trading week of 2022 at $259.50. At the current price, the stock has a dividend yield of 1.51%.

What To Expect From Eli Lilly Stock

Among 23 analysts polled via Investing.com, LLY stock has an outperform" rating.

LLY Consensus Estimates
LLY Consensus Estimates

Chart: Investing.com

Analysts also have a 12-month median price target of $283.03 on the stock, implying an increase of about 9% from current levels. The 12-month price range currently stands between $202 and $335.

LLY Fair Value
LLY Fair Value

Source: InvestingPro

However, according to a number of valuation models, like those that might consider P/E or P/S multiples, dividends or terminal values, the average fair value for LLY stock via InvestingPro stands at $259.62. In other words, most of the potential good news has likely already been baked into the Eli Lilly share price.

Meanwhile, we can look at the company’s financial health as determined by ranking more than 100 factors against peers in the healthcare sector. In terms of profit and price momentum health, Eli Lilly scores 4 out of 5 (top score). But growth and cash flow stand at 3. Its overall performance is rated “great.”

At present, P/E, P/B and P/S ratios for LLY stock are 39.4x, 30.3x and 8.5x. By comparison, those metrics for the peers stand at 16.6x, 4.7x and 4.0x. Put another way, Eli Lilly stock looks frothy compared to the average metrics in the healthcare sector.

Pharma Stock Ratio Comparison
Pharma Stock Ratio Comparison

We can also look at comparable ratios for several other pharma names via the chart above, such as AbbVie (NYSE:ABBV), AstraZeneca (NASDAQ:AZN), GlaxoSmithKline (NYSE:GSK), Merck (NYSE:MRK), Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY).

As these numbers highlight, fundamental values differ significantly across the sector. Therefore, readers who want to invest in individual healthcare names should do further due diligence before hitting the ‘buy’ button.

During the rest of January, we expect LLY stock to slide toward $250, after which it should trade sideways, possibly between $240 and $260. As a reminder, the company is set to announce its Q4 financials on Thursday, Feb. 3, before the opening bell. Therefore, volatility could increase in the first week of February as Wall Street digests the quarterly metrics.

Adding Eli Lilly Stock To Portfolios

LLY bulls with a two- to three-year horizon who are not concerned about short-term volatility could consider buying into the declines. The target would be $283.03, analysts' consensus expectation.

Alternatively, investors could consider buying an exchange traded fund (ETF) that has LLY as a holding. Examples would include:

  • Invesco Dynamic Pharmaceuticals ETF (NYSE:PJP)
  • Global X Aging Population ETF (NASDAQ:AGNG)
  • iShares MSCI USA Momentum Factor ETF (NYSE:MTUM)
  • ETC 6 Meridian Hedged Equity-Index Option Strategy ETF (NYSE:SIXH)

Finally, those who are experienced with options strategies and believe there could be further declines in Eli Lilly shares might prefer to do a bear put spread.

Most option strategies are not suitable for most retail investors. Therefore, the following discussion is offered for educational purposes and not as an actual strategy to be followed by the average retail investor.

Bear Put Spread On LLY Stock

Current Price: $259.50

In a bear put spread, a trader has a long put with a higher strike price as well as a short put with a lower strike price. Both legs of the trade have the same underlying stock (i.e. Eli Lilly here) and the same expiration date.

The trader wants LLY stock to decline in price. However, in a bear put spread, both the potential profit and the potential loss levels are limited.

Here's an example:

For the first leg of this strategy, the trader might buy an at-the-money (ATM) or slightly out-of-the-money (OTM) put option, like the LLY Feb. 18, 2022, 250-strike put option. This option is currently offered at $6.75. It would cost the trader $675 to own this put option, which expires in slightly over a month.

For the second leg of this strategy, the trader sells a put, like the LLY Feb. 18, 2022, 240-strike put option. This option’s current premium is $3.90. The option seller would receive $390, excluding trading commissions.

Maximum Risk

In our example, the maximum risk will be equal to the cost of the spread plus commissions. Here, the net cost of the spread is $2.85 ($6.75 – $3.90 = $2.85).

As each option contract represents 100 shares of the underlying stock, i.e. LLY, we’d need to multiply $2.85 by 100, which gives us $285 as the maximum risk.

The trader could easily lose this amount if the position is held to expiry and both legs expire worthless, i.e., if the Eli Lilly stock price at expiration is above the strike price of the long put (or $250.00 in our example).

Maximum Profit Potential

In a bear put spread, potential profit is limited to the difference between the two strike prices minus the net cost of the spread plus commissions.

So in our example, the difference between the strike prices is $10.00 ($250.00 – $240.00 = $10.00). And as we’ve seen above, the net cost of the spread is $2.85.

The maximum profit, therefore, is $7.15 ($10.00 – $2.85 = $7.15) per share less commissions. When we multiply $7.15 by 100 shares, the maximum profit for this option strategy comes to $715.

The trader will realize this maximum profit if the price of LLY stock is at or below the strike price of the short put (lower strike) at expiration (or $240.00 in our example).

Investors who have traded options before are likely to know that short put positions are typically assigned at expiration if the stock price is below the strike price (i.e., $240.00 here). However, there is also the possibility of early assignment. Therefore, the position would need monitoring up until expiration.

Break-Even LLY Price At Expiration

Finally, we should also calculate the break-even point for this trade. At that price, the trade will not gain or lose any money.

At expiration, the strike price of the long put (i.e., $250.00 in our example) minus the net premium paid (i.e., $2.85 here) would give us the break-even LLY price.

In our example: $250.00 − $2.85 = $247.15 (minus commissions).

Bottom Line

Long-term shareholders in Eli Lilly have seen excellent returns in the past several years. Wall Street credits innovation across its main therapeutic areas for the success of the group.

However, LLY stock started 2022 on a down note. We can possibly expect the volatility in the share price to continue for several more weeks as the company gets ready to report Q4 earnings. However, later in the year, shares of Eli Lilly should start a new leg higher.

3 Trades On Eli Lilly Stock As Pharma Investors Await Q4 Results
 

Related Articles

Tim Knight
Major U.S. Futures: Line Limits By Tim Knight - May 23, 2022 8

It would be easy to make an argument for either side at this point. For the bulls, one could argue that the market is deeply oversold and long overdue for a powerful counter-trend...

3 Trades On Eli Lilly Stock As Pharma Investors Await Q4 Results

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (5)
fun masti
fun masti Jan 11, 2022 11:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
all stock sell my pleace helps me why customers
re bo
re bo Jan 11, 2022 8:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
help me
jason chevalier
jason chevalier Jan 10, 2022 11:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
early morning sell off of Reviva Pharma is a mistake. They just got approved for phase three trials on their schizophrenia drug.
Princess Nhor Abedin
Princess Nhor Abedin Jan 10, 2022 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello
Elvis Okoh
Elvis Okoh Jan 10, 2022 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How are you doing
re bo
re bo Jan 10, 2022 8:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email